MR WITNESS: A Phase IIa Safety Study of Intravenous Thrombolysis With Alteplase in MRI-Selected Patients
Phase of Trial: Phase II
Latest Information Update: 24 Apr 2018
At a glance
- Drugs Alteplase (Primary)
- Indications Stroke
- Focus Adverse reactions
- Acronyms MR WITNESS
- 24 Apr 2018 Results (n=80) assessing whether intravenous thrombolysis 4.5 hours from the time of symptom discovery is safe in patients with qDFM, were published in the Annals of Neurology.
- 05 Apr 2017 New trial record
- 21 Mar 2017 Planned primary completion date changed from 1 Feb 2016 to 1 Jul 2016.